Who are larotaxel (RPR109881, XRP9881)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): VLI, Paclitaxel (Pac), Placebo plus Docetaxel, Paclitaxel (albumin-bound), ''albendazole'' and ''ivermectin'', Paclitaxel protein bound.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/larotaxel-rpr109881-xrp9881.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

larotaxel (RPR109881, XRP9881) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

larotaxel (RPR109881, XRP9881) (larotaxel (RPR109881, XRP9881)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane (microtubule stabilizer). Area: Oncology.

phase 3 Taxane (microtubule stabilizer) β-tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

larotaxel (RPR109881, XRP9881) (larotaxel (RPR109881, XRP9881)) — Sanofi. Larotaxel is a microtubule-stabilizing taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
larotaxel (RPR109881, XRP9881) TARGET	larotaxel (RPR109881, XRP9881)	Sanofi	phase 3	Taxane (microtubule stabilizer)	β-tubulin
VLI	VLI	Spectrum Pharmaceuticals, Inc	marketed	Vinca alkaloid	β-tubulin
Paclitaxel (Pac)	Paclitaxel (Pac)	Aravive, Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin / microtubules
Placebo plus Docetaxel	Placebo plus Docetaxel	Infinity Pharmaceuticals, Inc.	marketed	Taxane (microtubule stabilizer)	Microtubules (β-tubulin)
Paclitaxel (albumin-bound)	Paclitaxel (albumin-bound)	Dai, Guanghai	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)
''albendazole'' and ''ivermectin''	''albendazole'' and ''ivermectin''	Centre d'Appui à la lutte contre la Maladie	marketed	Antihelmintic/Antiparasitic agents	β-tubulin (albendazole); glutamate-gated chloride channels (ivermectin)
Paclitaxel protein bound	Paclitaxel protein bound	Barts & The London NHS Trust	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane (microtubule stabilizer) class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Infinity Pharmaceuticals, Inc. · 1 drug in this class
Sanofi · 1 drug in this class
University of Turin, Italy · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). larotaxel (RPR109881, XRP9881) — Competitive Intelligence Brief. https://druglandscape.com/ci/larotaxel-rpr109881-xrp9881. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab